Validation with big pharma – is it still necessary? Depends on who you talk to. This was one of several questions posed to panelists at today’s business roundtable session. Arguments can be made on both sides, but one thing is for certain, the life sciences financing community has become much more…

The biggest buzz aside from biotech at the CEO conference is definitely the light snowfall outside.  Word on the street is that it will continue to warm up and the snow won't stick, hopefully no one's travel will be dramatically inconvenienced tomorrow. If you want a second opinion: www.weather.com

Without a supportive legislative and regulatory environment, biotech companies cannot raise the funds necessary to get a product to market.  The panelists explored the pressing policy issues which could have a significant impact on the industry, from the creation of a pathway for the approval of…

The CEO & Investor Conference started out strong with several therapeutic workshops. The Pain “A Pain Free“ Guide to Current Therapies panel shared efforts to develop drugs with greater efficiency and fewer side-effects, including a patch for the site of pain (NeurogesX, Inc.), the use of…

There's a reason why they call it 'the largest investor conference focused on the biotech industry.' The next few days will bring out the major players in biotech, from investors to venture capitalists to companies with innovations worthy of writing home about. And the Daily Update is your cheat…

Two days until the CEO & Investor Conference! I'll be there, will you?